Original language | English (US) |
---|---|
Pages (from-to) | 713-715 |
Number of pages | 3 |
Journal | Transplantation |
Volume | 102 |
Issue number | 5 |
DOIs |
|
State | Published - May 1 2018 |
ASJC Scopus subject areas
- Transplantation
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Transplantation, Vol. 102, No. 5, 01.05.2018, p. 713-715.
Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - Ronald W. Busuttil, MD, PhD
T2 - William P. Longmire, JR, Chair of Surgery, Chief of Liver and Pancreas Transplantation, Director, UCLA-Dumont Transplant & Liver Cancer Center
AU - Busuttil, Ronald W.
N1 - Funding Information: been recently awarded a 5-year Program Project Grant from the NIH. As there are less than 10 program project grants in the country funded by the NIH that are related to organ transplantation, this is quite an achievement. The focus of the research on liver ischemia reperfusion injury (IRI) is both basic and translational since IRI contributes to poor graft function after transplantation. Minimizing the adverse effects of IRI could increase the number of patients that may successfully undergo liver transplantation. Our research has involved studying the platelet leukocyte endothelial cell interactions which play a central role in IRI. We were the first group to document that inhibition of P-Selectin activation by blocking P-Selectin glycoprotein ligand-1 was highly successful in increasing survival in marginal liver grafts after transplantation. I have been the principal investigator of these studies since they were initiated in the mid-1990s and currently these have been expanded to the clinical arena with Phase II clinical trials utilizing P-Selectin/ PSGL-1 blockade in both kidney and liver transplantation. In 2012, I was the lead author of a randomized placebo controlled phase II clinical trial comparing placebo versus selectin blockade in a series of 47 patients undergoing liver transplantation. Selectin blockade proved to be nontoxic and improved graft survival, liver function tests and biomarkers of inhibition of IRI. This study is the stimulus for a multicenter trial investigating selectin blockade as a mechanism to improve liver graft function and has applicability to other organ transplants.
PY - 2018/5/1
Y1 - 2018/5/1
UR - http://www.scopus.com/inward/record.url?scp=85059237008&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059237008&partnerID=8YFLogxK
U2 - 10.1097/TP.0000000000002077
DO - 10.1097/TP.0000000000002077
M3 - Comment/debate
C2 - 29702537
AN - SCOPUS:85059237008
SN - 0041-1337
VL - 102
SP - 713
EP - 715
JO - Transplantation
JF - Transplantation
IS - 5
ER -